PMID- 32866643
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20210623
IS  - 2213-7173 (Electronic)
IS  - 2213-7165 (Linking)
VI  - 23
DP  - 2020 Dec
TI  - Five-day antibiotic treatment for community-acquired bacterial pneumonia: A 
      systematic review and meta-analysis of randomized controlled trials.
PG  - 94-99
LID - S2213-7165(20)30210-1 [pii]
LID - 10.1016/j.jgar.2020.08.005 [doi]
AB  - OBJECTIVES: This systematic review and meta-analysis of randomized controlled 
      trials (RCTs) investigated whether the clinical efficacy of a 5-day antibiotic 
      course is comparable to that of a longer (>/=7 d) course for treating adults with 
      community-acquired bacterial pneumonia (CABP). METHODS: The PubMed, Web of 
      Science, Cochrane Library, Ovid MEDLINE, and Embase. were searched before January 
      18, 2020. RCTs comparing the efficacy of a 5-day antibiotic course with a longer 
      course (>/=7 d) for CABP treatment were included. Primary outcomes included the 
      clinical response, microbiological response, and risk of adverse events (AEs). 
      RESULTS: In this meta-analysis, 7 RCTs were included, and the 5-day antibiotic 
      courses group, and a longer course group comprised 1499 and 1522 patients, 
      respectively. The difference in the overall clinical response rates between the 
      5-day and longer courses (88.3% vs 88.8%, odds ratio [OR], 0.95, 95% confidence 
      interval [CI], 0.70-1.28, I(2) = 19%) was nonsignificant. Additionally, the 
      microbiological eradication rates did not differ significantly between the 
      groups, at 94.8% and 95.8% in the 5-day and longer courses groups, respectively 
      (OR, 0.84, 95% CI, 0.38-1.87, I(2) = 0%). Finally, all-cause mortality did not 
      differ between the 2 groups (OR, 0.91, 95% CI, 0.31-2.66, I(2) = 0%). 
      CONCLUSIONS: Five-day treatment and longer antibiotic courses for CABP yield 
      similar clinical and microbiological responses and exhibit similar safety 
      profiles.
CI  - Copyright (c) 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.
FAU - Lan, Shao-Huan
AU  - Lan SH
AD  - School of Pharmaceutical Sciences and Medical Technology, Putian University, 
      Putian 351100, China.
FAU - Lai, Chih-Cheng
AU  - Lai CC
AD  - Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan 
      Branch, Tainan, Taiwan.
FAU - Chang, Shen-Peng
AU  - Chang SP
AD  - Yijia Pharmacy, Tainan 70846, Taiwan.
FAU - Lu, Li-Chin
AU  - Lu LC
AD  - School of Management, Putian University, Putian 351100, China.
FAU - Hung, Shun-Hsing
AU  - Hung SH
AD  - Division of Urology, Department of Surgery, Chi-Mei Hospital, Chia Li, Tainan, 
      Taiwan. Electronic address: e197948@yahoo.com.tw.
FAU - Lin, Wei-Ting
AU  - Lin WT
AD  - Department of Orthopedic, Chi Mei Medical Center, Tainan 71004, Taiwan. 
      Electronic address: aapriliaa@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20200828
PL  - Netherlands
TA  - J Glob Antimicrob Resist
JT  - Journal of global antimicrobial resistance
JID - 101622459
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Adult
MH  - Anti-Bacterial Agents/adverse effects
MH  - *Community-Acquired Infections/drug therapy
MH  - Humans
MH  - *Pneumonia, Bacterial/drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Antibiotic
OT  - Bacterial Pneumonia
OT  - Community-acquired
OT  - Outcome
OT  - Short course
EDAT- 2020/09/01 06:00
MHDA- 2021/06/24 06:00
CRDT- 2020/09/01 06:00
PHST- 2020/06/22 00:00 [received]
PHST- 2020/07/17 00:00 [revised]
PHST- 2020/08/07 00:00 [accepted]
PHST- 2020/09/01 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2020/09/01 06:00 [entrez]
AID - S2213-7165(20)30210-1 [pii]
AID - 10.1016/j.jgar.2020.08.005 [doi]
PST - ppublish
SO  - J Glob Antimicrob Resist. 2020 Dec;23:94-99. doi: 10.1016/j.jgar.2020.08.005. 
      Epub 2020 Aug 28.